tirzepatide

01/01/2023 - "Tirzepatide is an agonist at both the GIPR and GLP-1R and is a highly effective treatment for type 2 diabetes and obesity3,4. However, although tirzepatide activates GIPR in cell lines and mouse models, it is not clear whether or how dual agonism contributes to its therapeutic benefit. "
11/01/2023 - "Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide."
01/01/2023 - "Tirzepatide: A New Generation Therapeutic for Diabetes Type 2."
01/01/2022 - "Tirzepatide is a potential new treatment option for Japanese patients with type 2 diabetes that is inadequately controlled with single oral antihyperglycaemic medication. "
11/01/2022 - "Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials."

01/01/2022 - "Tirzepatide highly effective for weight loss."
01/01/2023 - "Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients. "
07/01/2023 - "Additionally, the beneficial impact of tirzepatide on weight reduction has been corroborated in several studies, showing that this agent can achieve substantial and sustained weight loss in obese patients with or without T2D. "
01/01/2023 - "Tirzepatide has been evaluated in five published clinical trials (n=6278) within the SURPASS clinical trial programme, with a focus on glycaemic control and weight loss. "
01/01/2023 - "Scopus, PubMed/Medline, Web of Science, Cochrane, and Embase databases were searched using standard keywords to identify all controlled trials investigating the weight loss effects of Tirzepatide. "

01/01/2023 - "For body composition, tirzepatide 10 mg and 15 mg resulted in a significant reduction in body weight, and all doses of tirzepatide resulted in a significant reduction in body fat mass at Week 52. "
12/01/2018 - "Reductions in body weight were significantly greater with the LY3298176 1.5 mg, 4.5 mg and 10 mg doses versus placebo in MAD HS (LSM difference [95% CI]: -1.75 kg [-3.38, -0.12], -5.09 kg [-6.72, -3.46] and -4.61 kg [-6.21, -3.01], respectively) and doses of 10 mg and 15 mg had a relevant effect in T2DM patients (LSM difference [95% CI]: -2.62 kg [-3.79, -1.45] and -2.07 kg [-3.25, -0.88], respectively. "
12/01/2018 - "LY3298176 has the potential to deliver clinically meaningful improvement in glycaemic control and body weight. "
11/01/2022 - "A new and novel medication for the treatment of T2D, tirzepatide, a dual GIP/GLP-1RA, was approved by the FDA only one week after guidelines were published, and ongoing clinical trials demonstrate promising results not only for T2D but also for body weight and steatosis. "
08/21/2023 - "Among Hispanic/Latino and non-Hispanic/Latino patients treated with tirzepatide, respectively, HbA1c decreased significantly from baseline, ranging from 1.9% to 2.7% and 1.7% to 2.5%, and body weight decreased significantly from baseline, ranging from 5.3 kg to 12.4 kg and 6.5 kg to 17.1 kg (both P < 0.05) versus comparators across all trials. "

01/01/2021 - "Together, our studies show that tirzepatide improved insulin sensitivity in a weight-dependent and -independent manner. "
01/01/2023 - "Conclusion: Tirzepatide obviously exerts a protective effect against spatial learning and memory impairment, potentially through regulating abnormal insulin resistance and inflammatory responses."
03/06/2023 - "Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)."
01/01/2023 - "Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats."
01/01/2022 - "Tirzepatide has the ability to reduce glycaemic levels, improve insulin sensitivity, reduce body weight, and improve lipid metabolism, which is critically important in T2DM. "

11/01/2023 - "Tirzepatide: A promising treatment for obesity?"
01/01/2022 - "Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control."
11/01/2023 - "This article discusses tirzepatide as a treatment for obesity."
07/01/2023 - "Tirzepatide is not yet approved in the United States for obesity and its financial impact remains to be seen. "
03/01/2023 - "Future research should focus on investigating the role of tirzepatide in obesity, NASH, and cardio-renal benefits. "